Antiviral therapy and clinical outcome for patients with at least 2× increase from baseline antigenemia level
| . | . | Maintenance GCV or FOS n (%) . | Re-induction with GCV or FOS n (%) . |
|---|---|---|---|
| Patient characteristics | |||
| CMV serostatus | D+/R+ | 12 of 32 (38) | 6 of 15 (40) |
| D+/R− | 19 of 32 (59) | 9 of 15 (60) | |
| D−/R+ | 1 of 32 (3) | 0 of 15 (0) | |
| Donor type | Matched/related | 11 of 32 (34) | 2 of 15 (13) |
| Mismatched/unrelated | 21 of 32 (66) | 13 of 15 (87) | |
| GVHD grade | 0-1 | 1 of 32 (3) | 1 of 15 (7) |
| 2-4 | 31 of 32 (97) | 14 of 15 (93) | |
| Steroids | None | 1 of 32 (3) | 0 of 15 (0) |
| ≤1 mg/kg | 5 of 32 (16) | 1 of 15 (7) | |
| 1-2 mg/kg | 10 of 32 (31) | 4 of 15 (27) | |
| ≥2 mg/kg | 16 of 32 (50) | 10 of 15 (67) | |
| Ag up | >5× baseline | 16 of 32 (50) | 15 of 15 (100) |
| >10× baseline | 10 of 32 (31) | 12 of 15 (80) | |
| Initial Ag | 0.5-2 | 20 of 32 (63) | 5 of 15 (3) |
| 2.5-10 | 6 of 32 (19) | 6 of 15 (40) | |
| 10.5-50 | 3 of 32 (9) | 4 of 15 (27) | |
| >50 | 3 of 32 (9) | 0 of 15 (0) | |
| Maximum Ag | 1-50 | 25 of 32 (78) | 7 of 15 (47) |
| 51-100 | 3 of 32 (9) | 0 of 15 (0) | |
| 101-500 | 3 of 32 (9) | 2 of 15 (13) | |
| >500 | 1 of 32 (3) | 6 of 15 (40) | |
| Outcomes | |||
| CMV disease | ≤Day 100 | 4 of 32 (13) | 0 of 15 (0) |
| ≥Day 100 | 2 of 32 (6) | 2 of 15 (13) | |
| All-cause mortality | Day 100 | 6 of 32 (19) | 1 of 15 (7) |
| Day 365 | 13 of 32 (41) | 4 of 15 (27) | |
| Non-relapse mortality | Day 100 | 6 of 31 (19) | 1 of 14 (7) |
| Day 365 | 10 of 26 (38) | 4 of 14 (29) |
| . | . | Maintenance GCV or FOS n (%) . | Re-induction with GCV or FOS n (%) . |
|---|---|---|---|
| Patient characteristics | |||
| CMV serostatus | D+/R+ | 12 of 32 (38) | 6 of 15 (40) |
| D+/R− | 19 of 32 (59) | 9 of 15 (60) | |
| D−/R+ | 1 of 32 (3) | 0 of 15 (0) | |
| Donor type | Matched/related | 11 of 32 (34) | 2 of 15 (13) |
| Mismatched/unrelated | 21 of 32 (66) | 13 of 15 (87) | |
| GVHD grade | 0-1 | 1 of 32 (3) | 1 of 15 (7) |
| 2-4 | 31 of 32 (97) | 14 of 15 (93) | |
| Steroids | None | 1 of 32 (3) | 0 of 15 (0) |
| ≤1 mg/kg | 5 of 32 (16) | 1 of 15 (7) | |
| 1-2 mg/kg | 10 of 32 (31) | 4 of 15 (27) | |
| ≥2 mg/kg | 16 of 32 (50) | 10 of 15 (67) | |
| Ag up | >5× baseline | 16 of 32 (50) | 15 of 15 (100) |
| >10× baseline | 10 of 32 (31) | 12 of 15 (80) | |
| Initial Ag | 0.5-2 | 20 of 32 (63) | 5 of 15 (3) |
| 2.5-10 | 6 of 32 (19) | 6 of 15 (40) | |
| 10.5-50 | 3 of 32 (9) | 4 of 15 (27) | |
| >50 | 3 of 32 (9) | 0 of 15 (0) | |
| Maximum Ag | 1-50 | 25 of 32 (78) | 7 of 15 (47) |
| 51-100 | 3 of 32 (9) | 0 of 15 (0) | |
| 101-500 | 3 of 32 (9) | 2 of 15 (13) | |
| >500 | 1 of 32 (3) | 6 of 15 (40) | |
| Outcomes | |||
| CMV disease | ≤Day 100 | 4 of 32 (13) | 0 of 15 (0) |
| ≥Day 100 | 2 of 32 (6) | 2 of 15 (13) | |
| All-cause mortality | Day 100 | 6 of 32 (19) | 1 of 15 (7) |
| Day 365 | 13 of 32 (41) | 4 of 15 (27) | |
| Non-relapse mortality | Day 100 | 6 of 31 (19) | 1 of 14 (7) |
| Day 365 | 10 of 26 (38) | 4 of 14 (29) |
GCV, ganciclovir; FOS, foscarnet.